Patient inclusion in the International CytoSorb registry started in January 2015. This independent, multi-national registry is being managed by the Study Centre of the University of Jena, Germany under the direction of the internationally renowned sepsis researcher Professor Dr. med. Frank Brunkhorst and will systematically examine the benefits and safety of CytoSorb therapy under routine clinical conditions.
To our knowledge, CytoSorbents is the first medical technology company that has launched a new device-based therapy accompanied by a scientifically robust registry supervised by an independent scientific institution.
The registry will allow systematic investigation of the clinical effects of CytoSorb and thus contributes significantly to the expansion of knowledge about the CytoSorb therapy in many disease conditions.
CytoSorbents study ID |
Category |
Country |
Site |
Patient No. |
Status |
Registration |
S50.312-1 |
CytoSorb registry |
international |
coordinating center: Jena University |
open |
recruiting |
download Flyer